Literature DB >> 27652329

Tumor responsiveness to statins requires overexpression of the ARF6 pathway.

Hisataka Sabe1, Ari Hashimoto1, Shigeru Hashimoto1, Tsukasa Oikawa1.   

Abstract

The mevalonate pathway results in the prenylation of small GTPases, which are pivotal for oncogenesis and cancer malignancies. However, inhibitors of this pathway, such as statins, have not necessarily produced favorable results in clinical trials. We recently identified properties of statin responders, together with the underlying molecular mechanisms and simple biomarkers to predict these responders.

Entities:  

Keywords:  ARF6; cancer therapeutics; drug resistance; mevalonate pathway; statin

Year:  2016        PMID： 27652329      PMCID： PMC4972113          DOI： 10.1080/23723556.2016.1185564

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

Review 1.  Requirement for Arf6 in cell adhesion, migration, and cancer cell invasion.

Authors:  Hisataka Sabe
Journal:  J Biochem       Date:  2003-10       Impact factor: 3.387

2.  ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium.

Authors:  A Endo; M Kuroda; Y Tsujita
Journal:  J Antibiot (Tokyo)       Date:  1976-12       Impact factor: 2.649

Review 3.  Regulation of the mevalonate pathway.

Authors:  J L Goldstein; M S Brown
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

4.  Statin use and reduced cancer-related mortality.

Authors:  Sune F Nielsen; Børge G Nordestgaard; Stig E Bojesen
Journal:  N Engl J Med       Date:  2012-11-08       Impact factor: 91.245

Review 5.  Statins and breast cancer prognosis: evidence and opportunities.

Authors:  Thomas P Ahern; Timothy L Lash; Per Damkier; Peer M Christiansen; Deirdre P Cronin-Fenton
Journal:  Lancet Oncol       Date:  2014-09       Impact factor: 41.316

6.  GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion.

Authors:  Masaki Morishige; Shigeru Hashimoto; Eiji Ogawa; Yoshinobu Toda; Hirokazu Kotani; Mayumi Hirose; Shumei Wei; Ari Hashimoto; Atsuko Yamada; Hajime Yano; Yuichi Mazaki; Hiroshi Kodama; Yoshinori Nio; Toshiaki Manabe; Hiromi Wada; Hidenori Kobayashi; Hisataka Sabe
Journal:  Nat Cell Biol       Date:  2007-12-16       Impact factor: 28.824

7.  Co-overexpression of GEP100 and AMAP1 proteins correlates with rapid local recurrence after breast conservative therapy.

Authors:  Rumiko Kinoshita; Jin-Min Nam; Yoichi M Ito; Kanako C Hatanaka; Ari Hashimoto; Haruka Handa; Yutaro Otsuka; Shigeru Hashimoto; Yasuhito Onodera; Mitsuchika Hosoda; Shunsuke Onodera; Shinichi Shimizu; Shinya Tanaka; Hiroki Shirato; Mishie Tanino; Hisataka Sabe
Journal:  PLoS One       Date:  2013-10-07       Impact factor: 3.240

8.  Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer.

Authors:  Shigeru Hashimoto; Shuji Mikami; Hirokazu Sugino; Ayumu Yoshikawa; Ari Hashimoto; Yasuhito Onodera; Shotaro Furukawa; Haruka Handa; Tsukasa Oikawa; Yasunori Okada; Mototsugu Oya; Hisataka Sabe
Journal:  Nat Commun       Date:  2016-02-08       Impact factor: 14.919

Review 9.  The EGFR-GEP100-Arf6-AMAP1 signaling pathway specific to breast cancer invasion and metastasis.

Authors:  Hisataka Sabe; Shigeru Hashimoto; Masaki Morishige; Eiji Ogawa; Ari Hashimoto; Jin-Min Nam; Koichi Miura; Hajime Yano; Yasuhito Onodera
Journal:  Traffic       Date:  2009-04-21       Impact factor: 6.215

10.  P53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance.

Authors:  Ari Hashimoto; Tsukasa Oikawa; Shigeru Hashimoto; Hirokazu Sugino; Ayumu Yoshikawa; Yutaro Otsuka; Haruka Handa; Yasuhito Onodera; Jin-Min Nam; Chitose Oneyama; Masato Okada; Mitsunori Fukuda; Hisataka Sabe
Journal:  J Cell Biol       Date:  2016-04-04       Impact factor: 10.539
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.